Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors68

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors28

Views

Views
June 20250
July 202514
August 20251
September 20253
October 20252
November 20256
December 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil12
United States4
Argentina4
United Kingdom2
Guatemala1
Kenya1
Mexico1
Paraguay1
Turkey1
Venezuela1
 

Top cities views

Views
Rosario2
São Paulo2
Porto Alegre2
Americana1
Asunción1
Barão de Cocais1
Bauru1
Brasília1
Des Moines1
Fortaleza1